Compare WOR & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WOR | ZLAB |
|---|---|---|
| Founded | 1955 | 2013 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.4B |
| IPO Year | 1994 | 2017 |
| Metric | WOR | ZLAB |
|---|---|---|
| Price | $55.66 | $20.65 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $59.50 | $49.60 |
| AVG Volume (30 Days) | 128.1K | ★ 623.7K |
| Earning Date | 03-24-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.41% | N/A |
| EPS Growth | N/A | ★ 38.46 |
| EPS | ★ 2.17 | N/A |
| Revenue | ★ $1,153,762,000.00 | $460,156,000.00 |
| Revenue This Year | $22.21 | $9.75 |
| Revenue Next Year | $6.03 | $26.03 |
| P/E Ratio | $25.62 | ★ N/A |
| Revenue Growth | N/A | ★ 15.33 |
| 52 Week Low | $45.01 | $15.96 |
| 52 Week High | $70.91 | $44.34 |
| Indicator | WOR | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 54.20 | 49.55 |
| Support Level | $51.79 | $16.88 |
| Resistance Level | $56.11 | $25.28 |
| Average True Range (ATR) | 1.40 | 1.03 |
| MACD | -0.05 | -0.18 |
| Stochastic Oscillator | 61.64 | 57.91 |
Worthington Enterprises Inc is a designer and manufacturer of products and services, including manufactured metal products. The company operates under two reportable operating segments: Consumer Products and Building Products. The consumer Products business has a diverse product offering in the tools, outdoor living and celebrations categories, including propane-filled cylinders for torches, handheld torches, specialized hand tools, drywall tools, accessories and gas grills, and others. And the Building Products business engaged in providing pressurized containment solutions, providing critical components in the residential, non-residential, and repair and remodel end markets through essential categories. The company derives majority of the revenue from Building Products segment.
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.